Latest Basal Stories
BRIDGEWATER, N.J., Oct.
--- Data Presented at the American Association of Clinical Endocrinologists 23rd Annual Scientific and Clinical Congress --- BRIDGEWATER, N.J., May 15, 2014 /PRNewswire/ -- Valeritas,
LAUSANNE, Switzerland, January 29, 2014 /PRNewswire/ -- Click here for Picture 1 [http://www.debiotech.com/news/images/nw181_1.png ] The JewelPUMP2, which
BRIDGEWATER, N.J., July 25, 2011 /PRNewswire/ -- Valeritas, Inc., a medical technology company focused on the development and commercialization of innovative drug delivery solutions, announced today it received CE Mark approval for its V-Go(TM) Disposable Insulin Delivery Device as well as ISO 13485: 2003 Quality Management System Certification.
SAN DIEGO, June 27, 2011 /PRNewswire/ -- Ultra-long acting insulin degludec, under development by Novo Nordisk, lowers blood glucose levels with significantly reduced rates of hypoglycemia (low blood sugar) compared to insulin glargine, according to data presented at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego.
BRIDGEWATER, N.J., March 1, 2011 /PRNewswire/ -- Valeritas, Inc., a medical technology company committed to the development and commercialization of innovative drug delivery solutions, announced today that the U.S.
- The act of sweetening by admixture of some saccharine substance.